rs759834365
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our analyses suggested the G196A (Val66Met) polymorphism was significantly associated with cognitive impairment in PD, especially in Caucasian populations.
|
31365694 |
2019 |
rs759834365
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our meta-analysis implicates Val66Met BDNF polymorphism may be associated with Parkinson's disease cognitive impairment, further well-designed studies with larger populations are required to validate these results owing to the limited research.
|
31104169 |
2019 |
rs759834365
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Pattern of cortical thinning associated with the BDNF Val66Met polymorphism in Parkinson's disease.
|
31202861 |
2019 |
rs759834365
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The objective was to investigate if high cadence cycling altered non-motor cognition and depression symptoms in individuals with Parkinson's disease (PD) and whether exercise responses were influenced by brain-derived neurotrophic factor (BDNF) Val66Met polymorphism.
|
31197095 |
2019 |
rs759834365
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Here we review the role and relevance of the BDNF Val66Met polymorphism in neurodegenerative diseases, with particular emphasis on glaucoma, multiple sclerosis (MS), Alzheimer's disease (AD) and Parkinson's disease (PD).
|
29896439 |
2018 |
rs759834365
|
|
|
0.100 |
GeneticVariation |
BEFREE |
To determine whether dopaminergic (rs1076560 DRD2 G > T and rs4680 catechole-o-methyltranspherase (COMT) Val158Met) or brain derived neurotrophic factor (rs6265 BDNF Val66Met) genetic polymorphisms are associated with gait function and medication responsiveness in Parkinson's disease.
|
29249680 |
2018 |
rs759834365
|
|
|
0.100 |
GeneticVariation |
BEFREE |
A total of 27 individuals (age = 65.4 ± 8.1 years; males = 14, females = 13) with neurologist-diagnosed PD with 13 genotyped for BDNF as Val66Val, 11 as Val66Met, 2 as Met66Met (1 refused).
|
29547479 |
2018 |
rs759834365
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Association of BDNF Val66MET Polymorphism With Parkinson's Disease and Depression and Anxiety Symptoms.
|
27852165 |
2017 |
rs759834365
|
|
|
0.100 |
GeneticVariation |
BEFREE |
These results suggest a role for BDNF Val66Met polymorphism on cognitive impairment in PD.
|
26806863 |
2016 |
rs759834365
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The Val66Met polymorphism of BDNF (rs6265) has been associated with functional differences (mainly cognitive) between healthy adults and also with differences in the clinical expression of several other neuropsychiatric illnesses including PD.
|
25444596 |
2015 |
rs759834365
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our data do not support a major role for the BDNF Val66Met polymorphism in the pathogenesis of PD.
|
25431370 |
2015 |
rs759834365
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BDNF 196 G/A and 270 C/T polymorphisms and susceptibility to Parkinson's disease: a meta-analysis.
|
24329127 |
2014 |
rs759834365
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BDNF G196A (Val66Met) polymorphism associated with cognitive impairment in Parkinson's disease.
|
24394906 |
2014 |
rs759834365
|
|
|
0.100 |
GeneticVariation |
BEFREE |
No association between brain-derived neurotrophic factor G196A polymorphism and clinical features of Parkinson's disease.
|
24051673 |
2013 |
rs759834365
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In conclusion, there is no enough evidence for associations between BDNF polymorphisms (G196A and C270T) and PD risk at present.
|
23611539 |
2013 |
rs759834365
|
|
|
0.100 |
GeneticVariation |
BEFREE |
LRRK2 p.G2385R variant (odds ratio [OR] = 3.2; 95% confidence interval [CI] = 1.96-5.15, p < 0.0001), not BDNF p.V66M alone significantly increased the risk of PD.
|
21924942 |
2012 |
rs759834365
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Thus, we determined the distribution of BDNF Val66Met polymorphism in 184 Greek patients with sporadic PD and 113 control participants using polymerase chain reaction-restriction fragment length polymorphism, and explored the association of the polymorphism with certain clinical parameters of the disease.
|
22001244 |
2011 |
rs759834365
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Lrrk2 S1647T and BDNF V66M interact with environmental factors to increase risk of Parkinson's disease.
|
21167764 |
2011 |
rs759834365
|
|
|
0.100 |
GeneticVariation |
BEFREE |
G196A polymorphism is not a risk factor for PD and does not seem to modify clinical features in PD patients studied here.
|
20085561 |
2010 |
rs759834365
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BDNF Val66Met polymorphism is associated with cognitive impairment in Italian patients with Parkinson's disease.
|
19538209 |
2009 |
rs759834365
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease.
|
18977816 |
2009 |
rs759834365
|
|
|
0.100 |
GeneticVariation |
BEFREE |
This study examines whether BDNF V66M (c.196 G --> A) or NR4A2 IVS6 +18insG polymorphism is associated with the risk of Taiwanese PD and the age of onset using a case-control study.
|
17427185 |
2007 |
rs759834365
|
|
|
0.100 |
GeneticVariation |
BEFREE |
No association between the brain-derived neurotrophic factor 196 G>A or 270 C>T polymorphisms and Alzheimer's or Parkinson's disease.
|
16565926 |
2006 |
rs759834365
|
|
|
0.100 |
GeneticVariation |
BEFREE |
To date, there have been several conflicting reports on the correlation between AD or PD and Val66Met or C270T polymorphism in the BDNF promoter region, although no data on this relationship have been published with respect to dementia with Lewy bodies (DLB).
|
16899999 |
2006 |
rs759834365
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Overall, the meta-analysis of the allele contrast (A vs G) suggested large heterogeneity between studies (P=0.07, I2 =51%) and no association between G196A and the risk of developing PD: random effects odds ratio (OR)=1.00 [95% CI (0.85, 1.18)].
|
16172806 |
2005 |